blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News flashes

New version of the European Patent Register - SPC information for Unitary Patents.

2024-03-06

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP3511340

EP3511340 - HETERODIMERIC FC-FUSED CYTOKINE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME [Right-click to bookmark this link]
Former [2019/29]CYTOKINE FUSED TO IMMUNOGLOBULIN FC HETERODIMER AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
[2024/14]
StatusGrant of patent is intended
Status updated on  12.05.2024
Database last updated on 19.07.2024
FormerExamination is in progress
Status updated on  10.04.2024
FormerGrant of patent is intended
Status updated on  05.10.2023
FormerExamination is in progress
Status updated on  25.12.2020
FormerRequest for examination was made
Status updated on  14.06.2019
FormerThe international publication has been made
Status updated on  17.02.2018
Most recent event   Tooltip12.05.2024New entry: Communication of intention to grant a patent 
Applicant(s)For all designated states
Ajou University Industry-Academic Cooperation Foundation
206, World cup-ro
Yeongtong-gu
Suwon-si, Gyeonggi-do 16499 / KR
[2023/28]
Former [2019/29]For all designated states
Ajou University Industry-Academic Cooperation Foundation
206 World cup-ro
Yeongtong-gu
Suwon-si
Gyeonggi-do 16499 / KR
Inventor(s)01 / KIM, Yong Sung
6303-2502 (Raemian KwangKyo)
60, Central-ro, Yeongtong-gu
Suwon, 16504 / KR
02 / JUNG, Keunok
111-1301, 36, Gwongwang-ro
260 beon-gil, Yeongtong-gu
Suwon, 16532 / KR
03 / HA, Ji Hee
102-601, 6, Dongcheon-ro
Buk-gu
Daegu, 41431 / KR
04 / KIM, Ye Jin
202-104, 16, Hambakbong-ro
140 beon-gil, Buk-gu
Busan 46617 / KR
05 / CHOI, Dong Ki
105, 17, Jeonmin-ro 34beon-gil
Yuseong-gu, Daejeon 34052 / KR
06 / CHOI, Hye Ji
214-603, 21, Bongyeong-ro
1770 beon-gil, Yeongtong-gu
Suwon, 16713 / KR
 [2020/25]
Former [2019/29]01 / KIM, Yong Sung
110-1703
246 Gwongwang-ro
Paldal-gu
Suwon-si Gyeonggi-do 16534 / KR
02 / JUNG, Keunok
No. 301
23 World Cup-ro 151beon-gil
Yeongtong-gu
Suwon-si Gyeonggi-do 16501 / KR
03 / HA, Ji Hee
No. 502
7 World Cup-ro 193beon-gil
Yeongtong-gu
Suwon-si Gyeonggi-do 16502 / KR
04 / KIM, Ye Jin
102-102
100, Dadaenakjo 2-gil
Saha-gu
Busan 49497 / KR
05 / CHOI, Dong Ki
No 303, 77-31, Gwandeul 5-gil
Yuseong-gu, Daejeon 34019 / KR
06 / CHOI, Hye Ji
103-202
20, Munjang-ro 10-gil
Gumi-si
Gyeongsangbuk-do 39198 / KR
Representative(s)Haseltine Lake Kempner LLP
Cheapside House
138 Cheapside
London EC2V 6BJ / GB
[N/P]
Former [2019/29]Haseltine Lake Kempner LLP
Lincoln House, 5th Floor
300 High Holborn
London WC1V 7JH / GB
Application number, filing date17839824.410.08.2017
[2019/29]
WO2017KR08676
Priority number, dateKR2016010182310.08.2016         Original published format: KR 20160101823
[2019/29]
Filing languageKO
Procedural languageEN
PublicationType: A1 Application with search report
No.:WO2018030806
Date:15.02.2018
Language:KO
[2018/07]
Type: A1 Application with search report 
No.:EP3511340
Date:17.07.2019
Language:EN
[2019/29]
Search report(s)International search report - published on:KR15.02.2018
(Supplementary) European search report - dispatched on:EP18.02.2020
ClassificationIPC:C07K14/54, C07K14/59, A61K38/20, A61K38/24
[2019/29]
CPC:
C07K14/5434 (EP,KR,US); A61K38/208 (US); A61P35/00 (EP,KR);
C07K14/54 (EP,US); C07K14/59 (EP,US); A61K38/00 (EP,KR,US);
C07K2317/526 (KR); C07K2319/30 (EP,KR,US); Y02E60/10 (EP) (-)
Designated contracting statesAL,   AT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   RS,   SE,   SI,   SK,   SM,   TR [2019/29]
TitleGerman:HETERODIMERE FC-KONDENSIERTE ZYTOKINE UND PHARMAZEUTISCHE ZUSAMMENSETZUNG DAMIT[2024/14]
English:HETERODIMERIC FC-FUSED CYTOKINE AND PHARMACEUTICAL COMPOSITION COMPRISING THE SAME[2024/14]
French:HÉTÉRODIMÈRE FC-FUSIONNÉ CYTOKINE ET COMPOSITION PHARMACEUTIQUE LE COMPRENANT[2024/14]
Former [2019/29]AN IMMUNOGLOBULIN-FC HETERODIMER KONDENSIERTES ZYTOKIN UND PHARMAZEUTISCHE ZUSAMMENSETZUNG DAMIT
Former [2019/29]CYTOKINE FUSED TO IMMUNOGLOBULIN FC HETERODIMER AND PHARMACEUTICAL COMPOSITION COMPRISING SAME
Former [2019/29]CYTOKINE FUSIONNÉE À UN HÉTÉRODIMÈRE FC D'IMMUNOGLOBULINE ET COMPOSITION PHARMACEUTIQUE LA CONTENANT
Entry into regional phase27.02.2019Translation filed 
27.02.2019National basic fee paid 
27.02.2019Search fee paid 
27.02.2019Designation fee(s) paid 
27.02.2019Examination fee paid 
Examination procedure27.02.2019Examination requested  [2019/29]
16.09.2020Amendment by applicant (claims and/or description)
12.01.2021Despatch of a communication from the examining division (Time limit: M06)
22.07.2021Reply to a communication from the examining division
17.05.2022Despatch of a communication from the examining division (Time limit: M04)
23.09.2022Reply to a communication from the examining division
13.12.2023Communication of intention to grant the patent
10.04.2024Disapproval of the communication of intention to grant the patent by the applicant or resumption of examination proceedings by the EPO
13.05.2024Communication of intention to grant the patent
Fees paidRenewal fee
27.08.2019Renewal fee patent year 03
27.08.2020Renewal fee patent year 04
13.08.2021Renewal fee patent year 05
15.07.2022Renewal fee patent year 06
28.08.2023Renewal fee patent year 07
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Documents cited:Search[Y]US2010015089  (GILLIES STEPHEN D [US], et al) [Y] 1-15 * the whole document * * figures 1d, 3, 4; example -; claim - *;
 [Y]WO2014084607  (AJOU UNIV IND ACAD COOP FOUND [KR]) [Y] 1-15 * the whole document * * paragraph [[0239]]; figures 4, 7-19; claim - *;
 [Y]WO2014145907  (XENCOR INC [US], et al) [Y] 1-15 * paragraph [[0143]]; figures 33-35; claim - * * the whole document * * paragraphs [[0040]] , [ [0143] [0205]]; figures 33a,33B,34,35; claims 37, 47, 61, 68 * * paragraph [[0119]]; figure 36 * * paragraphs [[0108]] , [ [0239]]; figure 25 *;
 [Y]  - GILLIES S ET AL, "Antibody-IL-12 fusion proteins are effective in SCID mouse models of prostate and colon carcinoma metastases", THE JOURNAL OF IMMUNOLOGY,, (19980615), vol. 160, no. 12, ISSN 0022-1767, pages 6195 - 6203, XP002106576 [Y] 1-15 * the whole document *
 [Y]  - J. H. DAVIS ET AL, "SEEDbodies: fusion proteins based on strand-exchange engineered domain (SEED) CH3 heterodimers in an Fc analogue platform for asymmetric binders or immunofusions and bispecific antibodies", PROTEIN ENGINEERING DESIGN AND SELECTION, (20100204), vol. 23, no. 4, doi:10.1093/protein/gzp094, ISSN 1741-0126, pages 195 - 202, XP055018770 [Y] 1-15 * the whole document *

DOI:   http://dx.doi.org/10.1093/protein/gzp094
 [Y]  - Kannan Gunasekaran ET AL, "Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG (manuscript)", JBC Papers in Press, United States, doi:10.1074/jbc.M110.117382, (20100416), pages 1 - 20, URL: http://www.jbc.org/content/early/2010/04/16/jbc.M110.117382.full.pdf, (20190315), XP055569730 [Y] 1-15 * the whole document * * page 7, column 1, paragraph 2 *

DOI:   http://dx.doi.org/10.1074/jbc.M110.117382
 [A]  - GAFNER V ET AL, "An engineered antibody-interleukin-12 fusion protein with enhanced tumor vascular targeting properties", INTERNATIONAL JOURNAL OF CANCER, JOHN WILEY & SONS, INC, US, (20060705), vol. 119, no. 9, doi:10.1002/IJC.22101, ISSN 0020-7136, pages 2205 - 2212, XP002405179 [A] 1-15 * the whole document * * figure 1 *

DOI:   http://dx.doi.org/10.1002/ijc.22101
 [T]  - KEUNOK JUNG ET AL, "Heterodimeric Fc-fused IL12 shows potent antitumor activity by generating memory CD8 + T cells", ONCOIMMUNOLOGY, (20180306), vol. 7, no. 7, doi:10.1080/2162402X.2018.1438800, page e1438800, XP055653232 [T] * the whole document *

DOI:   http://dx.doi.org/10.1080/2162402X.2018.1438800
International search[Y]WO2014145907  (XENCOR INC [US], et al) [Y] 1-17 * See paragraphs [0108], [0141]-[0144], [0239], [0270]-[0271], [0374], [0387]; claim 61; and figures 25, 33. *;
 [Y]US2010015089  (GILLIES STEPHEN D [US], et al) [Y] 1-17 * See paragraphs [0003], [0014], [0023], [0046]; and figure 3. *;
 [A]KR20150008012  (HANMI PHARM IND CO LTD [KR]) [A] 1-17 * See abstract; claims 1, 2, 4, 10; and figure 1. *;
 [A]WO2014084607  (AJOU UNIV IND ACAD COOP FOUND [KR]) [A] 1-17 * See paragraph [0025]; claims 16, 24; and table 1. *;
 [A]  - LOW, S. C. et al., "Oral and Pulmonary Delivery of FSH-Fc Fusion Proteins via Neonatal Fc Receptor-mediated Transcytosis", Human Reproduction, (20050000), vol. 20, no. 7, doi:doi:10.1093/humrep/deh896, pages 1805 - 1813, XP002455704 [A] 1-17 * See pages 1806, 1812; and figure 1. *

DOI:   http://dx.doi.org/10.1093/humrep/deh896
 [PX]  - HA, JI-HEE et al., "Immunoglobulin Fc Heterodimer Platform Technology: from Design to Applications in Therapeutic Antibodies and Proteins", Frontiers in Immunology, (20161006), vol. 7, doi:doi:10.3389/fimmu.2016.00394, pages 1 - 16, XP055377975 [PX] 1-17 * See pages 1, 12; figures 1-2, 4; and table 1. *

DOI:   http://dx.doi.org/10.3389/fimmu.2016.00394
by applicantUS7695936
 KR101522954B
 KR20150142181
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.